Mind Medicine Stock
StockStockPrice
Frequently asked questions
What is Mind Medicine's market capitalization?
What is the Earnings Per Share (EPS) for Mind Medicine?
What are the analyst ratings and target price for Mind Medicine's stock?
What is the EBITDA for Mind Medicine?
What is the free cash flow of Mind Medicine?
What is the 5-year beta of Mind Medicine's stock?
How many employees does Mind Medicine have, and what sector and industry does it belong to?
What is the free float of Mind Medicine's shares?
Financials
Market Cap
$600.59M5Y beta
-6.67EPS (TTM)
-$1.987Free Float
72.50MEBITDA (TTM)
-$92.33MFree Cashflow (TTM)
-$74.34MPricing
Analyst Ratings
The price target is $24.25 and the stock is covered by 9 analysts.
Buy
8
Hold
1
Sell
0
Information
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
57
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker